RxDoctor Payments Data

Joan Allmon, MD

Internal Medicine · Collierville, TNNPI 1073516852

Payments from drug & device makers

$12,687in general payments, 2019–2025

Across 790 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • AbbVie$810
  • Amgen$678
  • GSK$539
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$12,664100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,687 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$413,755
Medicare patients
735
Services billed
15,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide171$181,122
EliquisApixaban76$79,520
MounjaroTirzepatide75$76,989
FarxigaDapagliflozin Propanediol77$72,293
JardianceEmpagliflozin46$44,352
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$35,501
TrulicityDulaglutide26$34,148
MyrbetriqMirabegron34$25,851
XareltoRivaroxaban16$15,391
Breo ElliptaFluticasone/Vilanterol16$14,735
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$11,347
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,328
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$10,165
LinzessLinaclotide12$8,658
Emgality PenGalcanezumab-Gnlm11$7,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,321$181,122171 claims
Lilly USA, LLCMounjaro, Trulicity$1,443$111,137101 claims
PfizerEliquis$508$79,52076 claims
AstraZenecaFarxiga$1,612$72,29377 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$539$60,56476 claims
Boehringer IngelheimJardiance$270$44,35246 claims
Astellas Pharma US IncMyrbetriq$160$25,85134 claims
Johnson & JohnsonXarelto$304$15,39116 claims
AbbVieLinzess, Synthroid$810$10,53367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Collierville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →